פריצת דרך דרמטית במלחמה בסרטן: החיסון שכבר עבר מבחן ענק

הערכה

A personalized mRNA vaccine has cleared a Phase 3 trial against melanoma, marking a concrete step forward for cancer immunotherapy. The same platform is now being tested against lung and pancreatic cancers. If the technology scales as researchers hope, producing a custom vaccine for each patient within weeks could become standard practice. The real test is whether these early results hold across larger, more diverse patient populations.